Boston Sci In China: Investment Chases Big Growth
This article was originally published in The Gray Sheet
Executive Summary
While Boston Scientific’s core cardiology business units continue to face steep growth challenges in the U.S, China’s massive population remains essentially an untapped market.
You may also be interested in...
Boston Scientific Continues Worldwide Restructuring, Plans Job Cuts
The cuts expand on a 2011 restructuring plan, with hopes of reducing operating expenses by up to $375 million at the end of 2013.
St. Jude Restructuring Will Cut 300 Jobs, Save Up To $60 Million In 2013
Move will realign four product divisions into two new operating units to support growth opportunities, help offset impact of 2.3% device tax set to take effect next year.
News In Brief
Consensus document issued on transcatheter heart valves. Boston Scientific launches Asia-Pacific organization. More news briefs.